Tech Company Financing Transactions
Confo Therapeutics Funding Round
On 7/26/2024, Confo Therapeutics raised $65 million in Series B funding from Ackermans & Van Haaren, BioGeneration Ventures and Capricorn Healthcare.
Transaction Overview
Company Name
Announced On
7/26/2024
Transaction Type
Venture Equity
Amount
$65,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance two, wholly owned programs through Phase 1 and two additional programs to IND approval, including molecules targeting GPR75 for obesity.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
Technologiepark-Zwijnaarde 30
Ghent/Zwijnaarde, 9052
Belgium
Ghent/Zwijnaarde, 9052
Belgium
Phone
Undisclosed
Website
Email Address
Overview
Confo Therapeutics' unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets. This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 7/26/2024: Terrantic venture capital transaction
Next: 7/26/2024: Greenely venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs